Cartilage extracellular matrix biosynthesis and turnover (ECM turnover)

Cartilage extracellular matrix (ECM) biosynthesis and turnover is a dynamic physiological process responsible for maintaining the structural integrity and mechanical properties of articular cartilage. The matrix is primarily composed of a dense network of type II collagen fibers and large aggregating proteoglycans, such as aggrecan, which are synthesized and maintained by resident chondrocytes (Sophia Fox et al., 2009, Sports Health). This homeostasis is regulated by a delicate balance between anabolic growth factors, such as TGF-beta and BMPs, and catabolic enzymes, specifically matrix metalloproteinases (MMPs) and aggrecanases like ADAMTS-4 and ADAMTS-5 (Malemud, 2019, International Journal of Molecular Sciences). In degenerative conditions like osteoarthritis, inflammatory cytokines such as IL-1 beta and TNF-alpha shift this balance toward excessive catabolism, leading to the progressive degradation of the collagenous framework and loss of proteoglycans (Kapoor et al., 2011, Nature Reviews Rheumatology). Therapeutic interventions, known as disease-modifying osteoarthritis drugs (DMOADs), aim to restore this equilibrium by either inhibiting degradative proteases or stimulating chondrocyte anabolic activity via pathways like FGF18 signaling (Lohmander et al., 2014, Annals of the Rheumatic Diseases). Monitoring the efficacy of these treatments often involves measuring biochemical markers of collagen turnover, such as CTX-II, which provide insights into the rate of tissue degradation (Mobasheri et al., 2017, Biomarkers).

Other names

Cartilage ECM metabolismCartilage matrix remodelingChondrocyte ECM homeostasisCartilage matrix turnover

Modulation of the balance between anabolic matrix synthesis and catabolic matrix degradation through growth factor agonism (e.g., FGF18) or protease inhibition (e.g., MMP and ADAMTS inhibitors).